Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828309 | 0.78 | OPRM1 (0.47) | TRPM8ALDH1A1OPRM1OPRL1 | |
| SCHEMBL3828306 | 0.78 | OPRM1 (0.47) | TRPM8ALDH1A1OPRM1OPRL1 | |
| SCHEMBL3834261 | 0.78 | OPRM1 (0.47) | TRPM8ALDH1A1OPRM1OPRL1 | |
| SCHEMBL23145404 | 0.75 | ALDH1A1 (0.38) | TRPM8ALDH1A1L3MBTL1CYP3A4TSHR | |
| SCHEMBL22906968 | 0.72 | OPRM1 (0.49) | ALDH1A1TSHROPRM1OPRL1 | |
| SCHEMBL15334888 | 0.72 | OPRM1 (0.49) | ALDH1A1TSHROPRM1OPRL1 | |
| SCHEMBL21384308 | 0.72 | TSHR (0.58) | ALDH1A1L3MBTL1CYP3A4TSHRMAPK1 | |
| SCHEMBL1612684 | 0.71 | L3MBTL1 (0.39) | TRPM8ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL4313351 | 0.71 | EPHX2 (0.44) | ALDH1A1L3MBTL1CYP3A4TSHRMAPK1 | |
| SCHEMBL20128961 | 0.71 | TSHR (0.46) | ALDH1A1L3MBTL1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | TRPM8 4674/4885ALDH1A1 971/4885L3MBTL1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.